# US 2026/0008792 A1 · Processes and compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0008792 A1
- Document ID: US20260008792A1
- Status: Published application
- Kind: A1
- Application number: 19/324,847
- Filed: 2025-09-10
- Published: 2026-01-08
- Earliest claimed: 2019-02-12
- Assignees: Radius Pharmaceuticals, Inc.
- Applicants: Radius Pharmaceuticals, Inc.
- Inventors: Michael MARKEY
- Web page: https://patentgrep.com/patent/US20260008792A1

## CPC

- C07F 5/025: {Boronic and borinic acid compounds}
- C07C 213/02: by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
- C07C 213/08: by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
- C07C 217/04: the carbon skeleton being acyclic and saturated
- C07C 217/84: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C07C 231/12: by reactions not involving the formation of carboxamide groups
- C07C 233/25: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 235/78: the carbon skeleton containing rings
- C07C 237/20: the carbon skeleton containing six-membered aromatic rings
- C07C 2602/28: Hydrogenated naphthalenes
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

## Claims

### Claim 1

A compound selected from (a), (b), (e), (f), and (g)

### Claim 2 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >50%.

### Claim 3 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >60%.

### Claim 4 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >70%.

### Claim 5 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >80%.

### Claim 6 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >90%.

### Claim 7 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >95%.

### Claim 8 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >98%.

### Claim 9 (depends on 1)

A compound of claim 1 having formula (e) or (g) wherein said compound is present in an enantiomeric excess of >99%.

### Claim at position 10

10-65. (canceled)

### Claim 66 (depends on 1)

The compound according to claim 1, wherein the compound is Compound (a):

### Claim 67 (depends on 1)

The compound according to claim 1, wherein the compound is Compound (b):

### Claim 68 (depends on 1)

The compound according to claim 1, wherein the compound is Compound (e):

### Claim 69 (depends on 1)

The compound according to claim 1, wherein the compound is Compound (f):

### Claim 70 (depends on 1)

The compound according to claim 1, wherein the compound is Compound (g):
